Arteriocyte awarded DARPA funding for company’s blood pharming technology
According to new research patients suffering chronic pain are more likely than others to consider suicide. A study by researchers in the United States found this increased risk remained even when the possible effect of mental illness was accounted for and the researchers say it provides further evidence of the need to be aware of
Full Post: Chronic pain makes many sufferers contemplate suicide
Arteriocyte announced today a $1,950,000 award from DARPA for the company’s Nanofiber Based System (NANEX) technology for the Production of Red Blood Cells project.
DARPA’s Blood Pharming program aims to develop an automated culture and packaging system that will yield a readily available, donorless supply of universal donor red blood cells in the military theatre. Arteriocyte is developing its NANEX technology in order to provide a continuous manufacturing system to enable the increased supply of universal donor red blood units.
In today’s widespread military deployments in the war on terror, advanced medical support requirements for military personnel have become an ever-growing challenge. As the most needed and vital component of blood, red blood cells (RBCs) are the most transfused blood product in battlefield trauma care. The NANEX system could ultimately deliver improved availability of fresh universal donor RBC supply in theatre that will help to address the inherent challenges of the donor system coupled with the global nature of U.S. military operations.
Working with technology developed at Johns Hopkins, Arteriocyte has developed its NANEX technology to enable rapid expansion of umbilical cord blood. The development program is designed to deliver a novel RBC manufacturing technology to help alleviate the military’s pressing need for constant supply of universal donor red blood units. The company’s development project is being conducted in collaboration with researchers at Johns Hopkins University, The Ohio State University and INSERM, Paris.
Arteriocyte, a clinical stage Biotechnology Company with facilities in Cleveland, Ohio and Hopkinton, Massachusetts, is developing proprietary stem cell therapies for human clinical applications. Arteriocyte’s goal is to develop commercially available stem cell based therapies using multiple sources of adult derived stem cells (marrow, peripheral cord blood, and cartilage). In October of 2007, Arteriocyte partnered with DW Healthcare Partners and Comerica to create Arteriocyte Medical Systems Inc., in order to commercialize and distribute novel medical devices and point of care surgical solutions to improve patient outcomes. Arteriocyte Medical Systems has a strategic partnership with Medtronic that includes a worldwide exclusive distribution agreement for Arteriocyte Medical System’s Magellan Autologous platelet separation device by Medronic’s Cardiac Surgery division. The Magellan system is in use in over 400 surgical centers worldwide today.
Taking blood stem cells collected from an umbilical cord into the lab and expanding their number before transplanting them to replace a patient’s blood supply is as safe as a standard cord blood transplant, researchers reported at the 50th Annual Meeting of the American Society of Hematology. In a first-of-its-kind randomized clinical trial, researchers at
Full Post: Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells
The University of California, San Diego Medical Center is the first hospital in California to enroll patients in a multi-center clinical trial, sponsored by Angioblast Systems Inc., to examine the safety and feasibility of administering adult stems cells to treat congestive heart failure. The cells, derived from bone marrow, are injected by a catheter directly
Full Post: Trial tests adult stems cells to treat congestive heart failure
To help provide a streamlined system for disposing of hazardous pharmaceutical waste that is protective of public health and the environment, the U.S. Environmental Protection Agency is proposing to add hazardous pharmaceutical waste to the Universal Waste Rule. The proposed rule encourages generators to dispose of pharmaceutical waste that is classified as non-hazardous under the
Full Post: EPA seeks public comment on proposal to add hazardous pharmaceutical waste to universal waste rule
A new study suggests that adult bone marrow stem cells can be used in the construction of artificial skin. The findings mark an advancement in wound healing and may be used to pioneer a method of organ reconstruction. The study is published in Artificial Organs , official journal of the International Federation for Artificial Organs
Full Post: Bone marrow stem cells used to regenerate skin
Two studies examining the effects of stem cell source and patient age on stem cell transplantation outcomes were explored at a press conference on Sunday, December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Preliminary results from a study examining a specialized technique for increasing the presence
Full Post: Effects of stem cell source and patient age on stem cell transplantation outcomes